ClinicalTrials.Veeva

Menu

Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy

Loma Linda University (LLU) logo

Loma Linda University (LLU)

Status

Terminated

Conditions

Melanoma
Kidney Cancer

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated Killer cells (LAK). This study will determine if these killer cells are able to kill certain standard cell-lines in the laboratory.

Full description

Blood samples will be taken from patients undergoing outpatient Interleukin-2 therapy to measure the LAK cytotoxicity at baseline, after 1 cycle of therapy and 2 months later. The LAK cytotoxicity assay will be a standard colorimetric assay that measures lactic dehydrogenase release from lysed cells.

Enrollment

11 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients must be undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center
  • Patients must sign and give written informed consent in accordance with institutional and federal guidelines

Exclusion criteria

  • Patients not undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center

Trial design

11 participants in 1 patient group

patients with melanoma or kidney cancer

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems